SRRK Stock Jumps on Resubmission of FDA Filing for SMA Drug

Shares of Scholar Rock jumped about 14% after the company resubmitted its FDA filing for SMA drug apitegromab, reviving approval hopes. The resubmission establishes a potential FDA decision timeline around September 2026, creating a binary regulatory catalyst that could materially affect the stock depending on future agency feedback.

Analysis

Shares of Scholar Rock jumped about 14% after the company resubmitted its FDA filing for SMA drug apitegromab, reviving approval hopes. The resubmission establishes a potential FDA decision timeline around September 2026, creating a binary regulatory catalyst that could materially affect the stock depending on future agency feedback.